Cell Therapy Expertise
cGMP Manufacturing, Infrastructure and Systems
Global Logistics and Storage
The Center for Innovation and Engineering
Strategic Manufacturing Assessment
Strategic Commercial Manufacturing Plan
PCT Pulse Blog
PCT in the News
PCT Industry News
A Cell Therapy Development, Manufacturing, and Commercialization Blog
Subscribe to Email Updates
Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN
December 16, 2016
December 15, 2016 – New York (N.Y.) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies ...
Kite announces positive topline KTE-C19 from ZUMA-1 pivotal trial
September 27, 2016
September 26, 2016 - Kite Pharma, Inc., (Nasdaq:KITE) today announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its ...
ImmunoCellular Therapeutics reports progress in two lead cancer immunotherapy programs
July 25, 2016
July 25, 2016 - In the ICT-107 phase 3 registrational trial, as of July 21, 2016, 109 patients have been screened in the US and Canada, with plans to ...
Kiadis Pharma’s Orphan Drug Designation for ATIR101™ further expanded to include treatment in a hematopoietic stem cell transplantation
June 30, 2016
June 30, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical ...
Kite Expands Development of TCR Therapies Targeting HPV-Associated Cancers in Partnership with NCI
June 20, 2016
June 20, 2016 - Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) ...
ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma
June 7, 2016
June 7, 2016 - ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the first patient has been treated in the ...
Kite Pharma and Cell Design Labs announce exclusive research collaboration using molecular 'on/off switches' for CAR T-cell immunotherapies
June 2, 2016
June 2, 2016 - Kite Pharma, Inc. (NASDAQ: KITE) ("Kite") and Cell Design Labs, Inc. today announced a research collaboration and license agreement to ...
ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma
May 6, 2016
May 6, 2016 - ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company has received approval from ...
Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications
May 3, 2016
May 02, 2016 - Kite Pharma, Inc. (Nasdaq:KITE) ("Kite"), a clinical-stage biopharmaceutical company focused on developing engineered autologous T ...
Subscribe to our blog for instant updates on challenges and trends in cell therapy development, manufacturing and commercialization.
© 2018 Hitachi Chemical Advanced Therapeutics Solutions, LLC